MX2022000603A - Anticuerpo anti-tau y uso del mismo. - Google Patents
Anticuerpo anti-tau y uso del mismo.Info
- Publication number
- MX2022000603A MX2022000603A MX2022000603A MX2022000603A MX2022000603A MX 2022000603 A MX2022000603 A MX 2022000603A MX 2022000603 A MX2022000603 A MX 2022000603A MX 2022000603 A MX2022000603 A MX 2022000603A MX 2022000603 A MX2022000603 A MX 2022000603A
- Authority
- MX
- Mexico
- Prior art keywords
- tau
- present
- tau antibody
- antibody according
- animal model
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190085233 | 2019-07-15 | ||
| PCT/KR2020/009207 WO2021010712A1 (ko) | 2019-07-15 | 2020-07-13 | 항-타우 항체 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000603A true MX2022000603A (es) | 2022-05-20 |
Family
ID=74088428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000603A MX2022000603A (es) | 2019-07-15 | 2020-07-13 | Anticuerpo anti-tau y uso del mismo. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220204601A1 (https=) |
| EP (1) | EP4001305A4 (https=) |
| JP (1) | JP7595061B2 (https=) |
| KR (1) | KR102196840B1 (https=) |
| CN (1) | CN114430744B (https=) |
| AU (1) | AU2020313751A1 (https=) |
| BR (1) | BR112022000719A2 (https=) |
| CA (1) | CA3143811A1 (https=) |
| CL (1) | CL2022000087A1 (https=) |
| GB (1) | GB2600599B (https=) |
| IL (1) | IL289813A (https=) |
| MX (1) | MX2022000603A (https=) |
| MY (1) | MY207132A (https=) |
| PH (1) | PH12022550106A1 (https=) |
| TW (1) | TW202116801A (https=) |
| WO (1) | WO2021010712A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
| MY198194A (en) | 2016-05-02 | 2023-08-09 | Prothena Biosciences Ltd | Antibodies Recognizing Tau |
| PT3452507T (pt) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
| KR102784294B1 (ko) | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| US20240376188A1 (en) * | 2021-09-09 | 2024-11-14 | The University Of North Carolina At Chapel Hill | Monoclonal antibodies targeting acetylated tau and methods of use thereof |
| US20250134952A1 (en) | 2021-09-20 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| WO2023229445A1 (ko) * | 2022-05-27 | 2023-11-30 | 주식회사 진큐어 | 신규 펩타이드 및 그의 용도 |
| CN115724967A (zh) * | 2022-09-21 | 2023-03-03 | 天津鸿宇泰生物科技有限公司 | 一种识别Tau蛋白N端区域的单克隆抗体及其应用 |
| EP4631975A1 (en) | 2022-12-08 | 2025-10-15 | Adel Inc. | Fusion comprising anti-tau antibody and peptide and use thereof |
| WO2024133723A1 (en) | 2022-12-22 | 2024-06-27 | Institut National de la Santé et de la Recherche Médicale | Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy |
| CN116716352A (zh) * | 2023-05-16 | 2023-09-08 | 深圳湾实验室 | Tau蛋白聚集的细胞模型、其构建方法及应用 |
| CN116693682B (zh) * | 2023-06-02 | 2024-04-19 | 涌源合生科技(深圳)有限公司 | 抗Tau蛋白抗体及其制备方法和用途 |
| CN116948025B (zh) * | 2023-09-14 | 2024-04-02 | 北京凯祥弘康生物科技有限公司 | 一种抗Tau蛋白的抗体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130251731A1 (en) * | 2012-03-22 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies |
| RU2644242C2 (ru) * | 2012-04-05 | 2018-02-08 | Ац Иммуне С.А. | Гуманизированное тау-антитело |
| SG10201708959WA (en) | 2012-07-03 | 2017-11-29 | Univ Washington | Antibodies to tau |
| TWI734975B (zh) * | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| TWI669314B (zh) * | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對ｔａｕ之抗體及其用途 |
| WO2018106889A1 (en) * | 2016-12-09 | 2018-06-14 | Cogwellin L.L.C. | Diagnosis of alzheimer's disease |
| KR102032314B1 (ko) * | 2016-12-21 | 2019-10-16 | 주식회사 아델 | 변이된 타우 단백질 단편 및 이의 용도 |
-
2020
- 2020-07-13 EP EP20841174.4A patent/EP4001305A4/en active Pending
- 2020-07-13 CN CN202080063893.8A patent/CN114430744B/zh active Active
- 2020-07-13 MY MYPI2022000234A patent/MY207132A/en unknown
- 2020-07-13 KR KR1020200086341A patent/KR102196840B1/ko active Active
- 2020-07-13 JP JP2022503414A patent/JP7595061B2/ja active Active
- 2020-07-13 GB GB2201160.5A patent/GB2600599B/en active Active
- 2020-07-13 WO PCT/KR2020/009207 patent/WO2021010712A1/ko not_active Ceased
- 2020-07-13 BR BR112022000719A patent/BR112022000719A2/pt unknown
- 2020-07-13 CA CA3143811A patent/CA3143811A1/en active Pending
- 2020-07-13 MX MX2022000603A patent/MX2022000603A/es unknown
- 2020-07-13 AU AU2020313751A patent/AU2020313751A1/en active Pending
- 2020-07-13 PH PH1/2022/550106A patent/PH12022550106A1/en unknown
- 2020-07-15 TW TW109123934A patent/TW202116801A/zh unknown
-
2022
- 2022-01-12 CL CL2022000087A patent/CL2022000087A1/es unknown
- 2022-01-12 IL IL289813A patent/IL289813A/en unknown
- 2022-01-12 US US17/574,227 patent/US20220204601A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022000087A1 (es) | 2023-03-10 |
| GB2600599B (en) | 2025-05-21 |
| MY207132A (en) | 2025-01-31 |
| AU2020313751A1 (en) | 2022-02-10 |
| EP4001305A1 (en) | 2022-05-25 |
| CN114430744A (zh) | 2022-05-03 |
| CN114430744B (zh) | 2024-06-21 |
| BR112022000719A2 (pt) | 2022-03-29 |
| EP4001305A9 (en) | 2023-05-24 |
| EP4001305A4 (en) | 2022-10-12 |
| GB2600599A8 (en) | 2024-12-25 |
| CA3143811A1 (en) | 2021-01-21 |
| TW202116801A (zh) | 2021-05-01 |
| PH12022550106A1 (en) | 2022-11-21 |
| IL289813A (en) | 2022-03-01 |
| JP2022541539A (ja) | 2022-09-26 |
| WO2021010712A1 (ko) | 2021-01-21 |
| KR102196840B1 (ko) | 2020-12-30 |
| JP7595061B2 (ja) | 2024-12-05 |
| GB2600599A (en) | 2022-05-04 |
| US20220204601A1 (en) | 2022-06-30 |
| GB202201160D0 (en) | 2022-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022000603A (es) | Anticuerpo anti-tau y uso del mismo. | |
| AR132544A2 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| BR112018073843A2 (pt) | anticorpos de peptídeo beta amiloide anti-n3pglu e usos dos mesmos | |
| MX2019007480A (es) | Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau. | |
| MX388142B (es) | Anticuerpos tau humanizados en enfermedad de alzheimer. | |
| CL2018000108A1 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| PE20170768A1 (es) | Anticuerpos de union a protofibrillas ab mejorados | |
| MX2017008277A (es) | Solucion oftalmica acuosa. | |
| JOP20220119A1 (ar) | أجسام مضادة trem2 واستخداماتها | |
| MX2019009860A (es) | Uso mejorado de neurotoxina botulinica en el tratamiento de sialorrea. | |
| EA202090944A1 (ru) | Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его | |
| MX389320B (es) | Anticuerpos anti-tnfrsf25 | |
| MX2019003805A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
| PH12019501064A1 (en) | Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | |
| MX392158B (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
| MX2017015462A (es) | Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas. | |
| MX2022009762A (es) | Moduladores del purinorreceptor 3 p2x (p2x3). | |
| EA202090945A1 (ru) | Анти-msln-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его | |
| BR112022011350A2 (pt) | Composições e métodos para tratamento e prevenção da influenza | |
| UY36262A (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| EA202091308A1 (ru) | Модифицированный вакцинный штамм brucella для лечения бруцеллеза | |
| CY1124821T1 (el) | Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ | |
| MX420767B (es) | Proteina de union al factor h modificada | |
| CL2025000935A1 (es) | Compuesto de anillo fusionado y producto farmacéutico que lo contiene. | |
| MX2022007919A (es) | Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii). |